(Corrects headline, first paragraph to remove 2017 revenue forecast, corrects to "lowered" from "raised" in the third paragraph)
Aug 8 (Reuters) - Endo International Plc reported a higher-than-expected quarterly profit, buoyed by higher sales from its sterile injectibles and U.S. branded drugs businesses.
Endo's shares were up 5.6 percent at $9.83 before the bell on Tuesday.
The Dublin, Ireland-based drugmaker lowered its full-year revenue forecast to $3.38 billion to $3.53 billion from $3.45 billion to $3.60 billion.
Excluding items, Endo earned 93 cents per share, above the average analyst estimate of 73 cents per share, according to Thomson Reuters I/B/E/S.
However, total revenue fell 4.9 percent to $875.7 million, hurt by weakness in Endo's U.S. generics business, but came in ahead of analysts' average estimate of $836.4 million.
Net loss from continuing operations was $696 million, or $3.12 per share, in the second quarter ended June 30, from a profit of $389.8 million, or $1.75 per share, a year earlier.
The drugmaker paid impairment charges of $725 million in the quarter, partly related to the withdrawal of its opioid painkiller Opana ER and the shutdown of its Alabama manufacturing facility.
Endo's results come a week after the world's No. 1 generics drugmaker Teva Pharmaceutical Industries Ltd posted a steeper-than-expected drop in its second-quarter earnings, hurt by accelerated price erosion in the United States. (Reporting by Akankshita Mukhopadhyay and Manas Mishra in Bengaluru; Editing by Martina D'Couto)